港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元同比增长约102.65%

智通财经01-12

重大事项：红星冷链(01641)：香港公开发售获2309.25倍认购每股发售价12.26港元BBSB INTL(08610)：公开发售获10745.13倍认购每股发售价0.6港元兆易创新(03986)香港公开发售获542.22倍认购全球发售净筹约46.11亿港元恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单百奥赛图-B(02315)通过基于选择权的评估框架与育...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602554921?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-12 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602554921","market":"sh","top_or_hot":-1,"title":"港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元 同比增长约102.65%","media":"智通财经","content":"<div>\n<p>重大事项：红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单百奥赛图-B(02315)通过基于选择权的评估框架与育...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391932.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元 同比增长约102.65%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元 同比增长约102.65%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 22:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1391932.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>重大事项：红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单百奥赛图-B(02315)通过基于选择权的评估框架与育...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391932.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1391932.html","article_id":"2602554921","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602554921","pubTimestamp":1768229718,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单百奥赛图-B(02315)通过基于选择权的评估框架与育","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","02359":"药明康德"},"translate_title":"Hong Kong Stock Announcement Nuggets | WuXi AppTec expects net profit attributable to the parent company to be approximately 19.151 billion yuan in 2025, a year-on-year increase of approximately 102.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1.5,"02359":1.5},"content_text":"重大事项：红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目剑桥科技(06166)控股子公司通过高新技术企业认定智谱(02513)回应与出行平台合作不涉内幕消息 业务推进属日常范畴中国软件国际(00354)投资企业MiniMax(00100)港交所上市 全栈AI战略版图再拓新篇达力普控股(01921)拟300万沙特里亚尔出售达力普国际40%股权 引入沙特战略投资者推进中东项目 1月13日复牌喜相逢集团(02473)附属拟透过股权收购或增资扩股方式取得旷时科技51%的股权吉宏股份(02603)拟设立深圳子公司 进一步完善公司包装业务布局经营业绩：药明康德(02359)发盈喜 预计2025年归母净利润约191.51亿元 同比增长约102.65%华润置地(01109)2025年累计合同销售金额约2336亿元 同比减少10.5%东风集团股份(00489)2025年度累计汽车销量为189.62万辆 同比增长约0.01%中银航空租赁(02588)2025年全年自有飞机利用率保持在100%龙湖集团(00960)2025年度累计实现总合同销售金额631.6亿元361度(01361)：主品牌产品第四季度的零售额同比取得约10%的正增长裕元集团(00551)2025年度综合累计经营收益净额80.31亿美元 同比减少1.85%丘钛科技(01478)12月手机摄像头模组销量为4308万件 环比增加13.2% 同比增加40.8%蓝月亮集团(06993)预计2025年度业绩显著改善亚太资源(01104)发盈喜 预期25╱26年财政年度上半年股东应占溢利约14亿至19亿港元 同比扭亏为盈中国利郎(01234)：第四季度“LILANZ”产品的零售金额同比取得高单位数增长","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602554921","isCrawlerRequest":true}

港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元 同比增长约102.65%

精彩评论

港股公告掘金 | 药明康德预计2025年归母净利润约191.51亿元同比增长约102.65%